These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21924008)

  • 21. Decision-making by healthcare payers.
    Levine M; Taylor R; Ryan M; Sculpher M
    Respir Med; 2002 Aug; 96 Suppl C():S31-8. PubMed ID: 12199490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A guide to health economic evaluations.
    Drug Ther Bull; 2010 Sep; 48(9):105-8. PubMed ID: 20810710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The challenges of economic evaluations of remote technical health interventions.
    Kennedy CA
    Clin Invest Med; 2005 Apr; 28(2):71-4. PubMed ID: 15909483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Principles of cost effectiveness analysis for the assessment of current and new therapies.
    Hillner BE; Smith TJ; Desch CE
    J Hematother; 1993; 2(4):501-6. PubMed ID: 8087498
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Economic evaluation of healthcare technologies: an introduction for physicians].
    Luengo-Fernández R; Hernández-Quesada C; Rivero-Arias O
    Rev Neurol; 2011 Jul; 53(2):107-15. PubMed ID: 21720981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost utility analysis based on a head-to-head Phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective.
    Pan F; Brazier NC; Shear NH; Jivraj F; Schenkel B; Brown R
    Value Health; 2011; 14(5):652-6. PubMed ID: 21839402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Economic analyses of health care. Cost benefit analyses promote better use of resources].
    Kristiansen IS
    Tidsskr Nor Laegeforen; 1990 Aug; 110(18):2377-81. PubMed ID: 2120789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic evaluation for ophthalmologists.
    Kuper H; Jofre-Bonet M; Gilbert C
    Ophthalmic Epidemiol; 2006 Dec; 13(6):393-401. PubMed ID: 17169853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conducting economic evaluations alongside multinational clinical trials: toward a research consensus.
    Reed SD; Anstrom KJ; Bakhai A; Briggs AH; Califf RM; Cohen DJ; Drummond MF; Glick HA; Gnanasakthy A; Hlatky MA; O'Brien BJ; Torti FM; Tsiatis AA; Willan AR; Mark DB; Schulman KA
    Am Heart J; 2005 Mar; 149(3):434-43. PubMed ID: 15864231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tackling wastage and inefficiency in the health sector.
    Parker D; Newbrander W
    World Health Forum; 1994; 15(2):107-13; discussion 114-31. PubMed ID: 8018273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modelling in the economic evaluation of health care: selecting the appropriate approach.
    Barton P; Bryan S; Robinson S
    J Health Serv Res Policy; 2004 Apr; 9(2):110-8. PubMed ID: 15099459
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
    Allen D; Rixson L
    Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Collection of health-economic data alongside clinical trials: is there a future for piggyback evaluations?
    O'Sullivan AK; Thompson D; Drummond MF
    Value Health; 2005; 8(1):67-79. PubMed ID: 15841896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Decision analytic modeling and their impact on health care decision making].
    Inotai A; Kaló Z; Mészáros A
    Acta Pharm Hung; 2009; 79(2):63-9. PubMed ID: 19634636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An introduction to economic evaluation: what's in a name?
    Hoch JS; Dewa CS
    Can J Psychiatry; 2005 Mar; 50(3):159-66. PubMed ID: 15830826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The role of economic analysis in health care].
    Kesteloot K
    Verh K Acad Geneeskd Belg; 1994; 56(3):191-202; discussion 202-9. PubMed ID: 8053263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions.
    Adang E; Voordijk L; Jan van der Wilt G; Ament A
    Health Policy; 2005 Oct; 74(2):146-56. PubMed ID: 16153475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health technology assessment and personalized medicine: are economic evaluation guidelines sufficient to support decision making?
    Husereau D; Marshall DA; Levy AR; Peacock S; Hoch JS
    Int J Technol Assess Health Care; 2014 Apr; 30(2):179-87. PubMed ID: 24806420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Squinting through layers of fog: assessing the cost effectiveness of treatments for multiple sclerosis.
    Hawton A; Shearer J; Goodwin E; Green C
    Appl Health Econ Health Policy; 2013 Aug; 11(4):331-41. PubMed ID: 23637055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.